|
|
|
| Changes of symptom groups in patients with esophageal cancer during chemotherapy and its implications |
| 1Xu Chunming,2Jiang Jing,3Mao Xiaoping |
| 1Department of Radiotherapy Nantong Cancer Hospital Nantong 226361 Jiangsu China
2Department of Radiology Hai'an Hospital
of Traditional Chinese Medicine Hai ' an 226600 Jiangsu China
3Department of Internal Medicine Nantong Cancer Hospital
Nantong 226361 Jiangsu China |
|
|
|
|
Abstract Objective To explore the symptom group composition and dynamic change track of patients with esophageal cancer
during chemotherapy and provide evidence for symptom management of patients with esophageal cancer during chemotherapy. Method
A total of 168 patients with esophageal cancer treated by chemotherapy in Nantong Cancer Hospital from June 2021 to December 2022
were selected as the study objects. General data questionnaire Anderson symptom assessment scale and symptom supplement
questionnaire were used at the first admission T1
first chemotherapy T2
second chemotherapy T3
and last chemotherapy T4
.
Symptom cluster were extracted by exploratory factor analysis. Result There were 12 20 22 and 18 symptoms with an incidence
greater than 20% at each time node from T1
to T4
respectively. The incidence ranged from 12. 50% to 94. 12%. Exploratory factor
analysis revealed Three five six and six symptom cluster were extracted from T1
T2
T3
and T4
respectively during chemotherapy for
patients with esophageal cancer. Among them sleep disorder symptom group cognitive-related symptom group and psychoneurotic
symptom group persisted from T1
to T4
pain symptom group digestive tract symptom group existed from T2
-T4
. Activity tolerance
symptom group existed in T3
- T4
. Conclusion Patients with esophageal cancer have multiple symptoms and high incidence during
chemotherapy and the composition of T3
and T4
symptom cluster is relatively stable. Nurses should pay attention to the symptom cluster
of postoperative patients with esophageal cancer during chemotherapy and take appropriate measures to actively intervene to alleviate
various symptoms so as to reduce the impact on patients.
|
|
Received: 22 February 2024
|
|
|
|
|
|
|
